Clinuvel opens new R&D centre in Singapore

Latest News

Clinuvel (ASX:CUV) has announced the opening of its centralised research and development centre in Singapore that will be operated by its subsidiary Vallaurix.

The company said the "bespoke" analytical and biological laboratories and offices will advance its R&D projects, expanding capacities in molecular profiling, peptide chemistry, and polymer and formulation sciences, as well as the capability to conduct ex-vivo experiments and bioassays, as well as studies on fresh biological and tissue cultures.

“In recent years Clinuvel has controlled its investments in new product development, building dedicated scientific teams worldwide and now opening its purpose-built facility in Singapore to expedite our research,” said chief scientific officer Dr Dennis Wright.

“Our research work with melanocortins – which target cells across the body and are known to have protective, anti-inflammatory and vasoactive effects, amongst others – focuses on translating our new molecules into safe, effective and clinically accepted pharmaceutical drugs for unmet patient needs.

"With Clinuvel’s first product already approved and being used to treat patients in Europe and the USA, the Vallaurix teams are working on second-generation melanocortins, as well as OTC products which leverage our expertise in related fields. The new facilities will enable Vallaurix to conduct a greater diversity of work inhouse, faster and more efficiently,” said Dr Wright.

The new facility replaces the previous laboratory which opened in 2014. Construction of the new facility commenced in 2019 but was delayed by four months due to government restrictions put in place to limit the spread of COVID-19. 

The company said Singapore was chosen as its main research centre because of its geographical location, excellent infrastructure and public safety, the education system and access to scientific talent.

“It is a privilege to see the planning of facilities coming to fruition, akin to scientific research projects becoming clinical reality,” said the head of the Vallaurix research and development centre, Dr Uma Rai.